Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: "Niki Karachaliou" Clear advanced filters

  • In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances.

    • Rafael Rosell
    • Niki Karachaliou
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 12, P: 75-76

  • Two phase III trials have shown that prolonging chemotherapy duration improves outcome in patients with nonsquamous non-small-cell lung cancer. Pemetrexed versus placebo, and pemetrexed–bevacizumab versus bevacizumab was tested in patients without disease progression after pemetrexed–cisplatin treatment. Biomarker-directed chemotherapy and/or targeted therapy could further improve treatment outcomes for patients with lung cancer.

    • Rafael Rosell
    • Niki Karachaliou
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 10, P: 549-550

  • Analysis of circulating tumour DNA (ctDNA) in blood samples provides a surrogate form of tumour biopsy (liquid biopsy) for determining EGFR and KRAS mutation status in patients with advanced-stage non-small-cell lung cancer. This approach obviates the need for a repeat biopsy, especially for the EGFR T790M mutation, which confers resistance to EGFR inhibition.

    • Rafael Rosell
    • Niki Karachaliou
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 13, P: 401-402